Mucopolysaccharidosis III Pipeline Summary

DelveInsight’s, “Mucopolysaccharidosis III - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Mucopolysaccharidosis III pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mucopolysaccharidosis III: Understanding

Mucopolysaccharidosis III: Overview

Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is an inherited lysosomal storage disorder characterized primarily by progressive central nervous system degeneration, leading to developmental delay, intellectual disability, behavioral abnormalities, sleep disturbances, and progressive loss of cognitive and motor abilities. Unlike many other mucopolysaccharidoses, the neurological manifestations are particularly prominent, while somatic features are generally milder. MPS III is classified into four subtypes- MPS IIIA, IIIB, IIIC, and IIID based on the specific lysosomal enzyme deficiency and corresponding gene involved.

MPS III is caused by biallelic pathogenic variants in one of four genes: SGSH, NAGLU, HGSNAT, or GNS, which encode enzymes involved in the degradation of heparan sulfate. The disease is inherited in an autosomal recessive manner. MPS IIIA is caused by SGSH variants, MPS IIIB by NAGLU variants, MPS IIIC by HGSNAT variants, and MPS IIID by GNS variants.

Deficiency of the respective lysosomal enzyme impairs the normal degradation of glycosaminoglycans (GAGs), particularly heparan sulfate, resulting in progressive intracellular accumulation of these substrates. This lysosomal storage primarily affects the central nervous system, leading to progressive neurodegeneration, developmental regression, intellectual disability, behavioral abnormalities, seizures, gait impairment, and eventually loss of motor and cognitive functions. GAG accumulation can also affect other tissues, producing skeletal, hearing, respiratory, cardiac, and gastrointestinal manifestations.

Diagnosis is based on suggestive clinical features and laboratory testing. Urinary GAG analysis, particularly assessment of heparan sulfate, can support suspicion of MPS III but cannot establish the specific subtype. Definitive diagnosis is made by demonstrating deficient activity of the relevant lysosomal enzyme and/or identifying biallelic pathogenic variants in SGSH, NAGLU, HGSNAT, or GNS through molecular genetic testing.

Currently, there is no clinically available disease-modifying treatment for the primary manifestations of MPS III. Management is therefore largely supportive and focuses on addressing developmental and behavioral problems, seizures, sleep disturbances, hearing and visual impairment, feeding difficulties, and musculoskeletal complications. Physical therapy, orthopedic care, educational and developmental support, and specialist management of cardiac and respiratory complications are used to maintain function and quality of life, while several disease-modifying approaches remain under investigation.

"Mucopolysaccharidosis III- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucopolysaccharidosis III pipeline landscape is provided which includes the disease overview and Mucopolysaccharidosis III treatment guidelines. The assessment part of the report embraces, in depth Mucopolysaccharidosis III commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucopolysaccharidosis III collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Mucopolysaccharidosis III R&D. The therapies under development are focused on novel approaches to treat/improve Mucopolysaccharidosis III.

Mucopolysaccharidosis III Emerging Drugs Chapters

This segment of the Mucopolysaccharidosis III report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mucopolysaccharidosis III Emerging Drugs

• Zafinofusp alfa (DNL126): Denali Therapeutics

DNL126 is an investigational enzyme replacement therapy which consists of recombinant N-sulfoglucosamine sulfohydrolase (SGSH) engineered with Denali’s Enzyme TransportVehicle™ (ETV) technology to facilitate transport across the blood–brain barrier. By delivering SGSH to the central nervous system and peripheral tissues, DNL126 is designed to restore lysosomal degradation of heparan sulfate and reduce its pathological accumulation, with the potential to address the neurological and systemic manifestations of MPS IIIA. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Mucopolysaccharidosis III.

• GC1130A: GC Biopharma Corp./ Novel Pharma

GC1130A is an investigational intracerebroventricular (ICV) enzyme replacement therapy (ERT) being developed by GC Biopharma Corp. in collaboration with Novel Pharma for the treatment of Sanfilippo syndrome type A (MPS IIIA). The therapy consists of recombinant human heparan N-sulfatase (rhHNS) and is administered directly into the cerebral ventricles via an intracerebroventricular access device to bypass the blood–brain barrier. GC1130A is intended to replace the deficient heparan N-sulfatase enzyme in patients with MPS IIIA, thereby reducing the accumulation of heparan sulfate, which causes central nervous system damage and progressive neurodegeneration. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Mucopolysaccharidosis III.

Further product details are provided in the report……..

Mucopolysaccharidosis III: Therapeutic Assessment

This segment of the report provides insights about the different Mucopolysaccharidosis III drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Mucopolysaccharidosis III

There are approx. 10+ key companies which are developing the therapies Mucopolysaccharidosis III. The companies which have their Mucopolysaccharidosis III drug candidates in the most advanced stage, i.e. Phase I/II include, Denali Therapeutics and others.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Mucopolysaccharidosis III pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mucopolysaccharidosis III: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucopolysaccharidosis III therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucopolysaccharidosis III drugs.

Mucopolysaccharidosis III Report Insights

• Mucopolysaccharidosis III Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mucopolysaccharidosis III Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mucopolysaccharidosis III drugs?
• How many Mucopolysaccharidosis III drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucopolysaccharidosis III?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mucopolysaccharidosis III therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mucopolysaccharidosis III and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Denali Therapeutics
• JCR pharmaceuticals
• GC Biopharma Inc.
• Novel Pharma

Key Products

• Zafinofusp alfa (DNL126)
• GC1130A
• JR-446
• JR-441